European Heart Journal Advance Access published online on February 22, 2006
European Heart Journal, doi:10.1093/eurheartj/ehi733
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Public Health, Health Economics Research Centre, Oxford University, Old Road Campus, Oxford OX3 7LF, UK
* To whom correspondence should be addressed. Aims Cardiovascular disease (CVD), together with its main components, coronary heart disease (CHD), and cerebrovascular diseases, is the main source of morbidity and mortality in the European Union (EU), but to date, there has not been any systematic cost-of-illness study to assess the economic impact of CVD in the EU. Methods and results CVD-related expenditure was estimated using aggregate data on morbidity, mortality, and healthcare resource use. Healthcare costs were estimated from expenditure on primary, outpatient, emergency, and inpatient care, as well as medications. Costs of unpaid care and lost earnings due to morbidity and premature death were included in the study. CVD was estimated to cost the EU Conclusion CVD is a leading public health problem. Our study is the first to assess the economic burden of CVD across the EU, and our results should help policy makers evaluate policy impact and prioritize research expenditures. However, because of data unavailability, our study has important limitations, which highlight the need for more accurate and comparable CVD-specific information.
Received May 6, 2005
Revised December 20, 2005
Accepted December 22, 2005
Clinical research
Economic burden of cardiovascular diseases in the enlarged European Union
José Leal 1 *,
Ramón Luengo-Fernández 1,
Alastair Gray 1,
Sophie Petersen 2,
and
Mike Rayner 2
2 Department of Public Health, British Heart Foundation Health Promotion Research Group, Oxford University, Old Road Campus, Oxford OX3 7LF, UK
José Leal, E-mail: jose.leal{at}dphpc.ox.ac.uk
Abstract 
169 billion annually, with healthcare accounting for 62% of costs. Productivity losses and informal care represented 21% and 17% of costs, respectively. CHD represented 27% and cerebrovascular diseases 20% of overall CVD costs.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. A.A. Fox, J.-P. Despres, A.-J. Richard, S. Brette, J. E. Deanfield, and on behalf of the IDEA Steering Committee and Natio Does abdominal obesity have a similar impact on cardiovascular disease and diabetes? A study of 91 246 ambulant patients in 27 European Countries Eur. Heart J., September 23, 2009; (2009) ehp371v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W Halliday, T. Lees, D. Kamugasha, R. Grant, A. Hoffman, P. M Rothwell, J. F Potter, M. Horrocks, R. Naylor, A. G Rudd, et al. Waiting times for carotid endarterectomy in UK: observational study BMJ, June 4, 2009; 338(jun04_1): b1847 - b1847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Luengo-Fernandez, A. M. Gray, and P. M. Rothwell Costs of Stroke Using Patient-Level Data: A Critical Review of the Literature Stroke, February 1, 2009; 40(2): e18 - e23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sousa, A. S. Uva, F. Pinto, and on behalf of the Investigators of PCI Registry of Risk-adjustment model in health outcomes evaluation: a contribution to strengthen assessment towards quality improvement in interventional cardiology Int. J. Qual. Health Care, October 1, 2008; 20(5): 324 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. G. Latronico, D. Catalucci, and G. Condorelli MicroRNA and cardiac pathologies Physiol Genomics, August 1, 2008; 34(3): 239 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chew, S. A Kausar, and S. Sturman Thrombolysis in acute ischaemic stroke pathway Intl J Care Pathw, January 1, 2008; 12(1): 10 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Stern Are We Getting Nearer to Screening for Atherosclerosis? Circulation, January 1, 2008; 117(1): 122 - 126. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur. Heart J., October 1, 2007; 28(19): 2375 - 2414. [Full Text] [PDF]
|
|
|
|
|
|
J. Escaned, L. Ryden, J. L. Zamorano, P. Poole-Wilson, V. Fuster, A. Gitt, F. Fernandez-Aviles, W. Scholte op Reimer, E. de Teresa, L. Alonso-Pulpon, et al. Trends and contexts in European cardiology practice for the next 15 years: The Madrid Declaration: a report from the European Conference on the Future of Cardiology, Madrid, 2-3 June 2006 Eur. Heart J., March 1, 2007; 28(5): 634 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Bhattacharyya, L. Perkins-Porras, D. L. Whitehead, and A. Steptoe Psychological and clinical predictors of return to work after acute coronary syndrome Eur. Heart J., January 2, 2007; 28(2): 160 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tendera How much does Europe invest in the treatment of cardiovascular diseases? Eur. Heart J., July 1, 2006; 27(13): 1521 - 1522. [Full Text] [PDF]
|
|